Effect of mupirocin in Helicobacter pylori in vitro

Masaaki  Minami; Takafumi  Ando; Hidemi  Goto; Michio  Ohta

doi:10.30574/gscarr.2021.8.1.0154

Authors

Masaaki Minami Department of Bacteriology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takafumi Ando Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hidemi Goto Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Michio Ohta Department of Molecular Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

DOI:

https://doi.org/10.30574/gscarr.2021.8.1.0154

Keywords:

Helicobacter pylori, Mupirocin, Time-kill curve, Electron microscopy, Postantibiotic effect

Abstract

Mupirocin (MUP) is an effective antibiotic against MRSA. Its bactericidal effect is stable under acid condition. By validating its antibacterial effect of Helicobacter pylori, we try to clarify MUP effect on H. pylori. The present study was conducted to investigate the effect of MUP on clarithromycin (CLR) / metronidazole (MNZ) -resistant and -susceptible strains of H. pylori, the time-kill effect of MUP, and the post antibiotic effect (PAE). We investigated the minimal inhibitory concentration (MIC) and the minimal bactericidal effect (MBC) of MUP against 140 H. pylori, which include clinical strains, ATCC43504, 26695 and J99. Ten of them were CLR -resistant strains and 3 were MNZ-resistant strains. The MIC₉₀ and MBC of MUP on all 140 strains is 0.064 μg / ml, and 0.1 μg / ml, respectively. There were no differences of MUP effect between susceptible and resistant strains either for CLR or MNZ. Time-kill curve test and PAE test of MUP on ATCC43504 were performed. By adding MUP, time-kill curve showed that bacterial quantities decreased in dose and time-dependent manner. No viable colony was found after 12-hour culture with 0.1 μg / ml MUP. The value of PAE is 12. MUP is a potential effective antibiotic for H. pylori even those for CLR / MNZ -resistant strains.

Metrics

Metrics Loading ...

References

Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 8390: 1311–1315.

Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J. Gastroenterol. Hepatol. 1991; 6: 105–113.

Yakoob J, Xuegong F, Guoling H, Li L, Zheng Z. Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J. Gastroenterol. Hepatol. 2001; 16: 981–985.

Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am. J. Gastroenterol. 1996; 91: 959–962.

Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann. Intern. Med. 1992; 116: 705–708.

Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is a major factor for gastric carcinoma in young patients. Scand. J. Gastroenterol. 2000; 35: 255–259.

Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosaassociated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342: 575–577.

National Institutes of Health. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272: 65–69.

The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. Gut. 1997; 41: 8–13.

Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idström JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1: 138–144.

Pilotto A, Franceschi M, Rassu M, Leandro G, Bozzola L, Furlan F, Di Mario F. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig. Liver Dis. 2000; 32: 667–672.

Hiyama T, Tanaka S, Masuda H, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumi M, Uemura N, Yoshihara M, Shimamoto F, Haruma K, Chayama K. Prevalence of Helicobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. J. Gastroenterol. Hepatol. 2003; 18: 1202–1207.

Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of MUP (pseudomonic acid), a new antibiotic for topical use. Antimicrob. Agents Chemother. 1985; 27: 495-498.

Sánchez JE, Sáenz NG, Rincón MR, Martín IT, Sánchez EG, Martínez MJ. Susceptibility of Helicobacter pylori to MUP, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000; 46: 283-285.

Minami M, Ando T, Hashikawa S, Torii K, Hasegawa T, Israel DA, Ina K, Kusugami K, Goto H, Ohta M. Effect of glycine on Helicobacter pylori in vitro. Antimicrob Agents Chemother. 2004; 48: 3782-3788.

National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing and approved standard M7-A6. 2003.

Craig WA, Gudmundsson S. Postantibiotic effect, In: V. Lorian V eds. Antibiotics in laboratory medicine. 2nd ed. Baltimore: Williams & Wilkins; 1996; 296-329.

Hassan IJ, Stark RM, Greenman J, Millar MR. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J Antimicrob Chemother. 1998; 42: 661-663.

Khoshnood S, Heidary M, Asadi A, Soleimani S, Motahar M, Savari M, Saki M, Abdi M. A review on mechanism of action, resistance, synergism, and clinical implications of MUP against Staphylococcus aureus. Biomed Pharmacother. 2019; 109: 1809-1818.